Answers are grounded in this paper and cite their sources.
In this issue of Blood, Heider et al describe the preclinical development of a novel Fc-engineered monoclonal antibody targeting the B-cell antigen CD37, an antigen that may have very different properties then CD20.
No takes yet. Share an insight, caveat, or question.
Ian W. Flinn (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: